브레포시티닙은 최초의 TYK2와 JAK1 이중 억제제로, TYK2 또는 JAK1을 단독으로 억제하는 약물에 비해 여러 염증성 자가면역질환에서 더 높은 효능을 기대할 수 있는 새로운 작용기전을 가지고 있습니다. 경구용 브레포시티닙은 관절형 건선, 심상성 건선, 궤양성 대장염, 원형탈모증, 농포성 땀샘염을 대상으로 한 5건의 위약 대조 임상 II상 시험을 포함해 14건의 완료된 임상 I상 및 임상 II상 시험에서 평가되고 있습니다. 이 5건의 위약 대조 임상 2상 시험은 모두 통계적으로 유의미하고 임상적으로 의미 있는 결과를 도출했습니다.
현재, 이 분자는 3개의 제III상 임상시험 VALOR(NCT05437263)에서 조사중이며, 2024년 12월까지 완료할 예정입니다.
주요 7개국의 브레포시티닙 시장에 대해 조사했으며, 시장의 개요와 2025-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 피부근염에 대한 브레포시티닙의 개요
- 제품 상세
- 임상 개발
- 기타 개발 활동
- 제품 개요
제3장 경쟁 구도(후기 단계 신규 치료법)
제4장 브레포시티닙 시장 평가
- 피부근염에 대한 브레포시티닙의 시장 전망
- 주요 7개국 시장 분석
- 주요 7개국에서 피부근염에 대한 브레포시티닙의 시장 규모
- 국가별 시장 분석
제5장 SWOT 분석
제6장 애널리스트의 견해
제7장 부록
제8장 DelveInsight의 서비스 내용
제9장 면책사항
제10장 DelveInsight 소개
제11장 리포트 구입 옵션
KSA
“"Brepocitinib Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about brepocitinib for dermatomyositis in the seven major markets. A detailed picture of the brepocitinib for dermatomyositis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the brepocitinib for dermatomyositis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the brepocitinib market forecast analysis for dermatomyositis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in dermatomyositis.
Drug Summary:
Brepocitinib is a potential first-in-class dual inhibitor of TYK2 and JAK1, a novel mechanism of action expected to potentially provide greater efficacy in multiple highly inflammatory autoimmune diseases as compared to agents that inhibit either TYK2 or JAK1 alone. Oral brepocitinib has been evaluated in 14 completed Phase I and Phase II studies, including five placebo-controlled Phase II studies in psoriatic arthritis, plaque psoriasis, ulcerative colitis, alopecia areata, and hidradenitis suppurativa. All five of these placebo-controlled Phase II studies generated statistically significant and clinically meaningful results.
Currently, the molecule is under investigation in a three Phase III clinical trial VALOR (NCT05437263), which is estimated to complete by December 2024.
Scope of the Report:
The report provides insights into:
- A comprehensive product overview including the brepocitinib description, mechanism of action, dosage and administration, research and development activities in dermatomyositis.
- Elaborated details on brepocitinib regulatory milestones and other development activities have been provided in this report.
- The report also highlights the brepocitinib research and development activities in dermatomyositis across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around brepocitinib.
- The report contains forecasted sales of brepocitinib for dermatomyositis till 2032.
- Comprehensive coverage of the late-stage emerging therapies for dermatomyositis.
- The report also features the SWOT analysis with analyst views for brepocitinib in dermatomyositis.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Brepocitinib Analytical Perspective by DelveInsight
In-depth Brepocitinib Market Assessment
This report provides a detailed market assessment of brepocitinib for dermatomyositis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
Brepocitinib Clinical Assessment
The report provides the clinical trials information of brepocitinib for dermatomyositis covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
- In the coming years, the market scenario for dermatomyositis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence brepocitinib dominance.
- Other emerging products for dermatomyositis are expected to give tough market competition to brepocitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of brepocitinib in dermatomyositis.
- Our in-depth analysis of the forecasted sales data of brepocitinib from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the brepocitinib in dermatomyositis.
Key Questions:
- What is the product type, route of administration and mechanism of action of brepocitinib?
- What is the clinical trial status of the study related to brepocitinib in dermatomyositis and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the brepocitinib development?
- What are the key designations that have been granted to brepocitinib for dermatomyositis?
- What is the forecasted market scenario of brepocitinib for dermatomyositis?
- What are the forecasted sales of brepocitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to brepocitinib for dermatomyositis?
- Which are the late-stage emerging therapies under development for the treatment of dermatomyositis?
Table of Contents
1. Report Introduction
2. Brepocitinib Overview in Dermatomyositis
- 2.1. Product Detail
- 2.2. Clinical Development
- 2.2.1. Clinical studies
- 2.2.2. Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
3. Competitive Landscape (Late-stage Emerging Therapies)
4. Brepocitinib Market Assessment
- 4.1. Market Outlook of Brepocitinib in dermatomyositis
- 4.2. 7MM Analysis
- 4.2.1. Market Size of Brepocitinib in the 7MM for dermatomyositis
- 4.3. Country-wise Market Analysis
- 4.3.1. Market Size of Brepocitinib in the United States for dermatomyositis
- 4.3.2. Market Size of Brepocitinib in Germany for dermatomyositis
- 4.3.3. Market Size of Brepocitinib in France for dermatomyositis
- 4.3.4. Market Size of Brepocitinib in Italy for dermatomyositis
- 4.3.5. Market Size of Brepocitinib in Spain for dermatomyositis
- 4.3.6. Market Size of Brepocitinib in the United Kingdom for dermatomyositis
- 4.3.7. Market Size of Brepocitinib in Japan for dermatomyositis
5. SWOT Analysis
6. Analysts' Views
7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
11. Report Purchase Options
